Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that autologous platelet-rich plasma increased hair growth potential by enhancing dermal papilla cell proliferation and stimulating key signaling pathways in both cell cultures and mice models.

This review evaluates the therapeutic potential of platelet-rich plasma for treating non-cicatricial alopecias and suggests it may be effective, though further research is needed to confirm its efficacy.

This chapter reviews procedural hair restoration techniques, including platelet-rich plasma and hair transplantation, and reports no new clinical findings.

This review discusses the potential benefits of PRP, exosomes, and stem cells in aesthetic medicine, noting the challenges in interpreting study results due to the lack of standardized protocols.

This overview of PRP Bristol clinics explains the growing popularity of Platelet-Rich Plasma therapy as a non-surgical treatment for early-stage hair loss, detailing its process, benefits, and suitability for individuals with androgenetic alopecia.

In this study, IFN-γ-stimulated iPSC-derived mesenchymal stem cell extracellular vesicles improved atopic dermatitis in mice by reducing Th2 cytokine activity, suppressing inflammation, and restoring skin barrier function, as evidenced by decreased itching and inflammatory markers.

This study reports the first identification of 'Candidatus Phytoplasma aurantifolia' in the invasive weed Eclipta prostrata in Taiwan, linked to symptoms such as branch proliferation and phyllody.

This study found that platelet rich plasma (PRP) is a safe and effective treatment for alopecia areata, with no significant difference in efficacy between activated and non-activated PRP.

This study examined 16 sporadic trichoblastic tumors and found that although one showed malignant transformation, clinical follow-up revealed no residual or metastatic disease. RNA sequencing indicated a high tumor mutational burden and absence of a UV-related signature, helping to distinguish these tumors from similar growths.

This review suggests that while platelet-rich plasma has the most robust clinical evidence, platelet-rich fibrin and concentrated growth factors are gaining favor due to their ease of use and absence of additives.

This study concluded that placental mesenchymal stem cells from aborted fetal tissue may serve as an in vitro model for studying spontaneous abortion mechanisms and potential regenerative therapies due to their abnormal gene expression and differentiation capabilities.

This review discusses the various applications of platelet-rich plasma in gynecology but presents no new experimental findings; the authors highlight its potential in managing conditions like Asherman’s syndrome and urinary incontinence.

This review explores the variability in platelet-rich plasma therapy outcomes across different medical applications, attributing disparities to inconsistent blood processing methods, and it reports no new clinical results.

This study found that platelet-rich plasma significantly accelerated wound healing in the donor area after follicular unit excision for hair transplantation in men.

Adding dalteparin and protamine microparticles to platelet-rich plasma can boost hair growth more than using platelet-rich plasma alone.

This study demonstrated that stem cells from the small intestine can differentiate into skin cells and reduce skin damage in irradiated mice, supporting the theory of stem cell plasticity.

This study found that repeated applications of both nonactivated and activated PRP in rats led to increased hypersensitivity to pain, which may be linked to elevated nerve growth factor levels and inflammatory mediators.

This study demonstrated that human iPSC-derived melanocytes, when transplanted into mice, can reconstitute pigmented hair follicles and integrate into normal tissue, suggesting their potential as a cellular therapy for depigmentation.

This study found that platelet-rich plasma injections significantly increased hair count and density in patients with male pattern hair loss without major side effects, suggesting it may be a safe and effective treatment option.

This review discusses the clinical manifestations and genetic basis of pigmentary mosaicism, highlighting its varied phenotypic expressions, but reports no new clinical results.

In this study, combining hair transplantation with platelet-rich plasma was found to be more effective than hair transplantation alone in reducing hair loss, improving hair regeneration, and decreasing skin lesions in patients with androgenic alopecia.

The abstract discusses the potential of platelet-rich plasma as a new, efficient, safe, and reproducible solution for hair loss and thinning, highlighting advancements in growth factors and stem cell technology. However, this summary does not report specific findings or results.

This study indicates that the protein Bcl-2 has a dual role, protecting hair follicle stem cells from apoptosis during regeneration and promoting tumor formation under oncogenic stress.

This study found that post-hematopoietic cell transplantation epidermal grafting significantly reduced chronic wound size in patients with recessive dystrophic epidermolysis bullosa.

This chapter reviews the presence and roles of stem cells in various body systems, focusing on their lifelong function in animals and humans, and reports no new experimental findings.

This review evaluates the use of platelet-rich plasma in dermatology, highlighting favorable outcomes in several areas, especially androgenetic alopecia, despite a lack of large randomized controlled trials and consistency in protocols.

A woman's skin symptoms led to a diagnosis of systemic AL amyloidosis, but she died from sepsis shortly after.

This review examines the current evidence for platelet-rich plasma in dermatology, finding favorable outcomes particularly for androgenetic alopecia, but highlights the need for more rigorous clinical trials and standardized protocols.

This review discusses various treatment challenges and toxicities in patients with relapsed follicular lymphoma and suggests that novel therapies could improve outcomes by reducing exposure to harmful chemotherapy cycles.